Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties
An active agent containing adhesive composition suitable for transdermal drug delivery having excellent water absorbability which comprises an effective amount of an active agent, an acrylate adhesive, a polyvinylpyrrolidone having a molecular weight of 1,000,000-5,000,000; a polyvinylpyrrolidone having a molecular weight of 2,000-50,000; a non-ionic surfactant; a terpene; and a dissolution assistant.
1. An active agent containing adhesive composition suitable for use in a matrix type transdermal patch consisting essentially of 1-25 wt. % of an active agent selected from the group consisting of diclofenac diethylammonium and diclofenac diethylanimonium salt, 40-95 wt. % of an acrylate adhesive, 1-7 wt. % of a polyvinylpyrrolidone having a molecular weight of 1,000,000-5,000,000; 1-13 wt. % of a polyvinylpyrrolidone having a molecular weight of 2,000-50,000; 0.1-25 wt. % of a non-ionic surfactant; 0.1-10 wt. % of a terpene; 0.1-10 wt. % of a dissolution assistant; and 0.5-5 wt. % of colloidal silica.
2. The composition according to claim 1 , wherein said acrylate adhesive is an acrylate polymer or a copolymer of acrylate and vinyl acetate.
3. The composition according to claim 1 , wherein said non-ionic surfactant is selected from the group consisting of glyceryl mono-oleate, glyceryl mono-laurate, sorbitan mono-oleate, glyceryl tri-oleate, isopropyl myristate, and a mixture thereof.
4. The composition according to claim 1 , wherein said terpene is selected from the group consisting of menthol, D-limonene, geraniol, nerolidol, and a mixture thereof.
5. The composition according to claim 1 , wherein said dissolution assistant is triacetin, isopropyl alcohol, propylene glycol, dimethylacetamide, propylene carbonate, diethylethanolaine, diethyl amine, triethylamine, N-methyl morphorine, benzylammonium chloride, and a mixture thereof.
6. A transdermal drug delivery system comprising an active agent containing adhesive matrix composition, a backing material superimposed on one surface of the matrix composition, the backing material being substantially impermeable to the active agent and a peelable release liner superimposed on the surface of the composition opposite the backing material, said matrix composition consisting essentially of 1-25 wt. % of an active agent selected from the group consisting of diclofenac diethylammonium and diclofenac diethylammonium salt, 40-95 wt. % of an acrylate adhesive, 1-7 wt. % of a polyvinylpyrrolidone having a molecular weight of 1,000,000-5,000,000; 1-13 wt. % of a polyvinylpyrrolidone having a molecular weight of 2,000-50,000; 0.1-25 wt. % of a non-ionic surfactant; 0.1-10 wt. % of a terpene; and 0.1-10 wt. % of a dissolution assistant; and 0.5-5 wt. % of colloidal silica.
7. The transdermal drug delivery system according to claim 6 , wherein said acrylate adhesive is an acrylate polymer or a copolymer of an acrylate polymer and vinyl acetate.
8. The transdermal drug delivery system according to claim 6 , wherein said non-ionic surfactant is selected from the group consisting of glyceryl mono-oleate, glyceryl mono-laurate, sorbitan mono-oleate, glyceryl tri-oleate, isopropyl myristate, and a mixture thereof.
9. The transdermal drug delivery system according to claim 6 , wherein said terpene is selected from the group consisting of menthol, D-limonene, geraniol, nerolidol, and a mixture thereof
10. The transdermal drug delivery system according to claim 6 , wherein said dissolution assistant is triacetin, isopropyl alcohol, propylene glycol, dimethylacetamide, propylene carbonate, diethylethanolaine, diethyl amine, triethylamine, N-methyl morphorine, benzylammonium chloride, and a mixture thereof.
11. A matrix type transdermal drug delivery patch comprising:
(1) a backing layer,
(2) an active agent containing adhesive composition which is laminated into two adhesive layers, between which is sandwiched an absorption enhancer layer comprising volatile constituents as absorption enhancers; and
(3) a release liner which is peelable prior to use;
wherein said active agent containing adhesive composition consists essentially of 1-25 wt. % of an active agent selected from the group consisting of diclofenac diethylammonium and diclofenac diethylammonium salt, 40-95 wt. % of an acrylate adhesive, 1-7 wt. % of a polyvinylpyrrolidone having a molecular weight of 1,000,000-5,000,000; 1-13 wt. % of a polyvinylpyrrolidone having a molecular weight of 2,000-50,000; 0.1-25 wt. % of a non-ionic surfactant; 0.1-10 wt. % of a terpene; 0.1-10 wt. % of a dissolution assistant; and 0.5-5 wt. % of colloidal silica.
12. The matrix type transdermal drug delivery patch of claim 11 , wherein said acrylate adhesive is an acrylate polymer or a copolymer of an acrylate polymer and vinyl acetate.
13. The matrix type transdermal drug delivery patch of claim 11 , wherein said non-ionic surfactant is selected from the group consisting of glyceryl mono-oleate, glyceryl mono-laurate, sorbitan mono-oleate, glyceryl tri-oleate, isopropyl myristate, and a mixture thereof.
14. The matrix type transdermal drug delivery patch of claim 11 , wherein said terpene is selected from the group consisting of menthol, D-limonene, geraniol, nerolidol, and a mixture thereof.
15. The matrix type transdermal drug delivery patch of claim 11 , wherein said dissolution assistant is triacetin, isopropyl alcohol, propylene glycol, dimethylacetamide, propylene carbonate, diethylethanolaine, diethyl amine, triethylamine, N-methyl morphorine, benzylammonium chloride, and a mixture thereof.